Powered by

Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 07, 2019 - PR Newswire
Financial Results

PR Newswire

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company's recent achievements and anticipated upcoming milestones.  

"We are excited by the continued strong momentum across our business," stated Matthew R. Patterson, Ch...